Trung Huynh
Stock Analyst at UBS
(4.78)
# 105
Out of 5,124 analysts
56
Total ratings
71.05%
Success rate
30.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $771.87 | -14.49% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,074.68 | +0.50% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $174.04 | +28.13% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.83 | +1,266.12% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $327.31 | -3.15% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $27.16 | +39.91% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.90 | +0.40% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $53.94 | +0.11% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.19 | +219.63% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $9.40 | +38.30% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $206.95 | -15.44% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $105.26 | +19.70% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $228.49 | -25.60% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.35 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $771.87
Upside: -14.49%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,074.68
Upside: +0.50%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $174.04
Upside: +28.13%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.83
Upside: +1,266.12%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $327.31
Upside: -3.15%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $27.16
Upside: +39.91%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.90
Upside: +0.40%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $53.94
Upside: +0.11%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.19
Upside: +219.63%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $9.40
Upside: +38.30%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $206.95
Upside: -15.44%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $105.26
Upside: +19.70%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $228.49
Upside: -25.60%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.35
Upside: -